Navigation Links
VaxGen Reports Financial Update
Date:3/6/2008

ion shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

VaxGen, Raven and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of VaxGen in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus described above. Additional information regarding the directors and executive officers of VaxGen is also included in VaxGen's definitive proxy statement for its 2007 Annual Meeting of Stockholders which was filed with the SEC on November 21, 2007 and its Annual Report on Form 10-K for the year ended December 31, 2006, which was filed with the SEC on August 30, 2007. These documents are available free of charge at the SEC's web site at http://www.sec.gov and from Investor Relations at VaxGen as described above.

- FINANCIAL CHARTS TO FOLLOW -

Selected Consolidated Financial Information

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

Year Ended December 31,

2007 2006

Revenues:

Research contracts, grants and other services $5,011 $13,205

Related party ser
'/>"/>

SOURCE VaxGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
2. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
3. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
4. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
5. VaxGen Addresses MPM Claims in Letter to Stockholders
6. VaxGen Files Last Outstanding Periodic Report With SEC
7. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
8. VaxGen Files First Quarter 2007 Financials
9. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/26/2015)... ... 26, 2015 , ... The 2015 Epigenomics & Metabolomics Meeting in ... Asymmetrex to share the first report on progress with its crowdsourcing campaign ... adult tissue stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... News Facts, , ... life sciences industry -- including,biopharmaceutical companies, contract ... increasingly turning to Oracle(R) Remote,Data Capture (RDC) ... effectively. , , -- ...
... Mealey,s Conferences (now HB,Litigation Conferences) released its upcoming schedule ... for women in the legal profession. , , ... 22 - Asbestos Gaskets: Exposure and the State of the ... , February 5 - Nanotechnology: ...
... Jan. 20 Amgen (Nasdaq: AMGN ) today ... full year financial results on Monday, Jan. 26, 2009 after ... followed by a conference call with the investment community at ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
Cached Biology Technology:Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 2Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 3Life Sciences Organizations Choose Oracle to Accelerate and Simplify Clinical Trial Data Collection 4Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences 2Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results 2
(Date:8/26/2015)... , August 26, 2015 The ... and Five Factor), Application (Travel & Immigration, Government, Banking, ... Global Forecast to 2020", published by MarketsandMarkets, Multi-Factor Authentication ... 2020, growing at a CAGR of 17.7% between 2015 ... 82 F igures spread through 169 ...
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/24/2015)... TOWN, South Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and ... with the "2015 African Biometrics Company of the Year ... in Nigeria .   -Cross ... and http://www.presseportal.de/nr/8896 - On Thursday evening, ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... at Rutgers University studying the cause of a rare ... adolescence say new findings may provide clues to understanding ... developing better tools to treat them. In today,s ... Herrup, Ronald Hart and Jiali Li in the Department ...
... University of Miami Miller School of Medicine researchers played ... genetics collaboration to date, which identified 11 new regions ... doubling the number of potential genetics-based therapeutic targets to ... the study gives a broader view of the genetic ...
... specific neural cell types are essential for studies ... Culturing Neural Cells: A Laboratory Manual provides step-by-step ... tissues and culturing them under conditions that closely ... detail how to dissect the brain, spinal cord, ...
Cached Biology News:Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 2Rare childhood disease may hold clues to treating Alzheimer's and Parkinson's 3International collaboration finds 11 new Alzheimer's genes to target for drug discovery 2
Applications: Western blotting ...
... entry by collecting data from any RS232 ... Collect is extremely easy to use and ... entry. An excellent solution for collecting ... force gauges, digital calipers, bar code readers, ...
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Biology Products: